Apr 21, 2014 at 14:42 | Source: CNBC-TV18
Nischal Maheshwari of Edelweiss Financial Services is neutral on pharmaceutical space.
Apr 21, 2014 at 13:18 | Source: Moneycontrol.com
Nifty is bound in a trading range of 6675-6828 points and many people will interpret this as a head and shoulder pattern, albeit a short term topping pattern.
Apr 18, 2014 at 14:32 | Source: Reuters
Medicines produced in India, which supplies about 40 percent of generic and over-the-counter drugs sold in the United States, have come under increased scrutiny by the Food and Drug Administration over the past year.
Apr 17, 2014 at 08:23 | Source: Moneycontrol.com
Indian ADRs ended mixed on Wednesday. Dr Reddy's Laboratories shed 1.61 percent and Tata Motors advanced 2 percent.
Apr 16, 2014 at 10:18 | Source: Moneycontrol.com
Dr Reddys Laboratories has launched Eszopiclone Tablets (C-IV) 1 mg, 2 mg and 3 mg, a therapeutic equivalent generic version of LUNESTA tablets C-IV in the US market on April 15, 2014, following the approval by the USFDA.
Apr 16, 2014 at 08:28 | Source: Moneycontrol.com
Indian ADRs ended mostly lower on Tuesday. Wipro gained more than 2 percent, while Infosys plunged 4.68 percent.
Apr 15, 2014 at 14:16 | Source: Reuters
The Suprax recall is the second for India's fourth-largest drugmaker by sales, after pulling nearly 65,000 bottles from the US in January last year because of discoloration.
Apr 15, 2014 at 08:23 | Source: Moneycontrol.com
Indian ADRs ended higher on Monday. ICICI Bank jumped 1.41 percent and Infosys rose 4.57 percent.
Apr 12, 2014 at 13:21 | Source: CNBC-TV18
Tirthankar Patnaik, Director at Institutional Research, Religare Capital Markets recommends buying Infosys from the IT pack. He is overweight on IT and pharma.
Apr 12, 2014 at 11:56 | Source: CNBC-TV18
Tirthankar Patnaik bearish on financials and public sector lenders, but State Bank of India is the stock from the PSB pack which he likes.